Ceo
CurrentElypta is developing a novel liquid biopsy platform for multiple cancer indications. The technology is based on measurement of a system biomarker (17 metabolites) found in blood and urine and scoring algorithms for identification and refinement of signatures for specific cancer indications. Our mission is to improve outcomes for cancer patients through earlier detection and closer tracking of disease.